

RSV Prevention Strategy in High-Risk Infants with Beyfortus[®]

Beyfortus[®] is recommended by the JCVI in high-risk groups, including¹:



Infants born **very or extremely pre-term (GA <32 weeks)**



Infants with **chronic lung disease of prematurity (CLD) / bronchopulmonary dysplasia (BPD)**



Pre-term infants with **congenital heart disease (CHD)**



Children **<24 months** of age with **severe combined immunodeficiency syndrome (SCID)**

Beyfortus® is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:²



i. Neonates and infants during their first RSV season;

ii. Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Beyfortus® should be used in accordance with official recommendations.²

Prescribing Information
can be found by scanning
or clicking this QR code



Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on Tel: 0800 0902 314.

Alternatively, send via email to
UK-drugsafety@sanofi.com.

References

1. Public Health England. (2026). Chapter 27a: Respiratory syncytial virus (RSV). In Immunisation against infectious disease (The Green Book). 2. Beyfortus. Summary of Product Characteristics (SmPC).